Metsera, a biotech focused on obesity treatments, came out of stealth only this year, and its lead drug is still in early ...

The race to supply obesity drugs is so competitive that one early-stage startup is already striking a deal for commercial ...

Amneal Pharmaceuticals (AMRX) and Metsera have entered into a collaboration agreement to enable the efficient development and ...

Modine , a diversified global leader in thermal management technology and solutions, announced today that Mark Bendza will join the company's Board of Directors effective immediately. Mr. Bendza ...

Breast cancer remains the most common cancer among women in Canada, but early detection can save lives. PocketHealth is ...

Obesity startup Metsera is getting a new manufacturing partner and a new CEO. On Tuesday, the well-funded startup announced ...

Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company"), a global pharmaceutical company, and Metsera, Inc. ("Metsera"), a clinical-stage biopharmaceutical company accelerating the ...

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

Chicago-based venture-capital firm Arch Venture Partners has closed a new $3 billion fund to invest in early-stage ...

A biotech-focused venture capital firm in Chicago is ready with a new fund as life sciences and biotech continue to find new ...

Today, a brief rundown of news from Biogen, as well as updates from Dyne Therapeutics, Denali Therapeutics and Novo Nordisk that you may have missed.

New revelations from the showdown between Novo Nordisk’s CEO and Bernie Sanders’ Senate health committee Tuesday; PhRMA’s legal victory in IRA case; the federal interest rate cut and anticipated ...